diff --git a/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md b/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md
index f3abe5e21..229d6eeb2 100644
--- a/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md
+++ b/domains/grand-strategy/ai-weapons-governance-tractability-stratifies-by-strategic-utility-creating-ottawa-treaty-path-for-medium-utility-categories.md
@@ -11,11 +11,14 @@ attribution:
   sourcer:
     - handle: "leo"
       context: "Leo (synthesis from US Army Project Convergence, DARPA programs, CCW GGE documentation, CNAS autonomous weapons reports, HRW 'Losing Humanity' 2012)"
-related: ["the legislative ceiling on military ai governance is conditional not absolute cwc proves binding governance without carveouts is achievable but requires three currently absent conditions"]
+related:
+- the legislative ceiling on military ai governance is conditional not absolute cwc proves binding governance without carveouts is achievable but requires three currently absent conditions
 supports:
 - Binding international AI governance achieves legal form through scope stratification — the Council of Europe AI Framework Convention entered force by explicitly excluding national security, defense applications, and making private sector obligations optional
+- Ottawa model treaty process cannot replicate for dual-use AI systems because verification architecture requires technical capability inspection not production records
 reweave_edges:
 - Binding international AI governance achieves legal form through scope stratification — the Council of Europe AI Framework Convention entered force by explicitly excluding national security, defense applications, and making private sector obligations optional|supports|2026-04-04
+- Ottawa model treaty process cannot replicate for dual-use AI systems because verification architecture requires technical capability inspection not production records|supports|2026-04-07
 ---
 
 # AI weapons governance tractability stratifies by strategic utility — high-utility targeting AI faces firm legislative ceiling while medium-utility loitering munitions and autonomous naval mines follow Ottawa Treaty path where stigmatization plus low strategic exclusivity enables binding instruments outside CCW
@@ -40,4 +43,4 @@ Relevant Notes:
 - [[ai-weapons-stigmatization-campaign-has-normative-infrastructure-without-triggering-event-creating-icbl-phase-equivalent-waiting-for-activation]]
 
 Topics:
-- [[_map]]
+- [[_map]]
\ No newline at end of file
diff --git a/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md b/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md
index 3b9fe1dda..5ecf1452f 100644
--- a/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md
+++ b/domains/health/cipla-dual-role-generic-semaglutide-and-branded-tirzepatide-exemplifies-portfolio-hedge-strategy-for-bifurcated-markets.md
@@ -10,8 +10,12 @@ agent: vida
 scope: functional
 sourcer: Medical Dialogues
 related_claims: ["[[tirzepatide-patent-thicket-extends-exclusivity-to-2041-bifurcating-glp1-market-into-commodity-and-premium-tiers]]"]
+supports:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
+reweave_edges:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036|supports|2026-04-07
 ---
 
 # Cipla's dual role as generic semaglutide entrant AND Lilly's branded tirzepatide partner exemplifies the portfolio hedge strategy for pharmaceutical companies navigating market bifurcation
 
-Cipla, India's major generic manufacturer, is simultaneously positioned as (1) the likely dominant generic semaglutide entrant following March 2026 patent expiry and (2) Eli Lilly's exclusive distribution partner for branded tirzepatide (Yurpeak) targeting smaller Indian cities. This dual positioning represents a sophisticated portfolio hedge: Cipla captures the high-volume, low-margin generic semaglutide market (where price competition will be intense) while also building a higher-margin branded tirzepatide position with Lilly's backing. The strategy works because the two drugs serve different market segments post-bifurcation: generic semaglutide for price-sensitive patients and payers, branded tirzepatide for those willing to pay premium for incremental efficacy. Cipla's 'evaluating' language around semaglutide launch timing (despite patent expiry) suggests coordination with the tirzepatide rollout to avoid cannibalizing their own premium product. This portfolio approach allows pharmaceutical companies to profit from both the commodity price war and the premium tier, rather than being forced to choose one positioning. The strategy is only viable when patent timelines create sufficient separation between products—the 10-15 year tirzepatide exclusivity gap makes the hedge work.
+Cipla, India's major generic manufacturer, is simultaneously positioned as (1) the likely dominant generic semaglutide entrant following March 2026 patent expiry and (2) Eli Lilly's exclusive distribution partner for branded tirzepatide (Yurpeak) targeting smaller Indian cities. This dual positioning represents a sophisticated portfolio hedge: Cipla captures the high-volume, low-margin generic semaglutide market (where price competition will be intense) while also building a higher-margin branded tirzepatide position with Lilly's backing. The strategy works because the two drugs serve different market segments post-bifurcation: generic semaglutide for price-sensitive patients and payers, branded tirzepatide for those willing to pay premium for incremental efficacy. Cipla's 'evaluating' language around semaglutide launch timing (despite patent expiry) suggests coordination with the tirzepatide rollout to avoid cannibalizing their own premium product. This portfolio approach allows pharmaceutical companies to profit from both the commodity price war and the premium tier, rather than being forced to choose one positioning. The strategy is only viable when patent timelines create sufficient separation between products—the 10-15 year tirzepatide exclusivity gap makes the hedge work.
\ No newline at end of file
diff --git a/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md b/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md
index 10a99e0fc..a04eb6279 100644
--- a/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md
+++ b/domains/health/clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance.md
@@ -13,9 +13,11 @@ related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because
 supports:
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 reweave_edges:
 - FDA MAUDE reports lack the structural capacity to identify AI contributions to adverse events because 34.5 percent of AI-device reports contain insufficient information to determine causality|supports|2026-04-07
 - FDA's MAUDE database systematically under-detects AI-attributable harm because it has no mechanism for identifying AI algorithm contributions to adverse events|supports|2026-04-07
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities|supports|2026-04-07
 ---
 
 # The clinical AI safety gap is doubly structural: FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm
diff --git a/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md b/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md
index 9a45d4c15..d200740c3 100644
--- a/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md
+++ b/domains/health/cvd-mortality-stagnation-affects-all-income-levels-indicating-structural-system-failure.md
@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: Leah Abrams, Neil Mehta
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+related:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
+reweave_edges:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|related|2026-04-07
 ---
 
 # CVD mortality stagnation after 2010 affects all income levels including the wealthiest counties indicating structural system failure not poverty correlation
 
-The pervasive nature of CVD mortality stagnation across all income deciles—including the wealthiest counties—demonstrates this is a structural, system-wide phenomenon rather than a poverty-driven outcome. While county-level median household income was associated with the absolute level of CVD mortality, ALL income deciles experienced stagnating CVD mortality declines after 2010. This finding is crucial because it rules out simple socioeconomic explanations: if CVD stagnation were primarily driven by poverty, inequality, or lack of access to care, we would expect to see continued improvements in affluent populations with full healthcare access. Instead, even the wealthiest counties show the same pattern of flattening mortality improvements. This suggests the binding constraint is not distributional (who gets care) but structural (what care is available and how the system operates). The fact that nearly every state showed this pattern at both midlife (ages 40-64) and old age (ages 65-84) reinforces that this is a civilization-level constraint, not a regional or demographic phenomenon.
+The pervasive nature of CVD mortality stagnation across all income deciles—including the wealthiest counties—demonstrates this is a structural, system-wide phenomenon rather than a poverty-driven outcome. While county-level median household income was associated with the absolute level of CVD mortality, ALL income deciles experienced stagnating CVD mortality declines after 2010. This finding is crucial because it rules out simple socioeconomic explanations: if CVD stagnation were primarily driven by poverty, inequality, or lack of access to care, we would expect to see continued improvements in affluent populations with full healthcare access. Instead, even the wealthiest counties show the same pattern of flattening mortality improvements. This suggests the binding constraint is not distributional (who gets care) but structural (what care is available and how the system operates). The fact that nearly every state showed this pattern at both midlife (ages 40-64) and old age (ages 65-84) reinforces that this is a civilization-level constraint, not a regional or demographic phenomenon.
\ No newline at end of file
diff --git a/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md b/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md
index 61d93d911..7b5b5256f 100644
--- a/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md
+++ b/domains/health/cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths.md
@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: Shiels MS, Chernyavskiy P, Anderson WF, et al. (NCI)
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
+supports:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
+reweave_edges:
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
 ---
 
 # CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
 
-NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 years in men. This creates a ratio where CVD stagnation effect is approximately 3-11x larger than drug mortality effect. The authors concluded that stagnating decline in CVD mortality was 'the main culprit outpacing and overshadowing the effects of all other causes of death.' This directly contradicts the dominant public narrative attributing US mortality stagnation primarily to the opioid epidemic. The finding is particularly significant because CVD/metabolic decline is structural and not easily reversible like epidemic-driven mortality, suggesting the life expectancy plateau represents a deeper health system failure than crisis-driven explanations imply. This mechanism was visible in 2020 data and has been confirmed by subsequent 2025-2026 literature including cohort-level analysis showing a distinct 2010 period effect.
+NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 years in men. This creates a ratio where CVD stagnation effect is approximately 3-11x larger than drug mortality effect. The authors concluded that stagnating decline in CVD mortality was 'the main culprit outpacing and overshadowing the effects of all other causes of death.' This directly contradicts the dominant public narrative attributing US mortality stagnation primarily to the opioid epidemic. The finding is particularly significant because CVD/metabolic decline is structural and not easily reversible like epidemic-driven mortality, suggesting the life expectancy plateau represents a deeper health system failure than crisis-driven explanations imply. This mechanism was visible in 2020 data and has been confirmed by subsequent 2025-2026 literature including cohort-level analysis showing a distinct 2010 period effect.
\ No newline at end of file
diff --git a/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md b/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md
index 7fa4f3abb..8af2149b7 100644
--- a/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md
+++ b/domains/health/generic-digital-health-deployment-reproduces-existing-disparities-by-disproportionately-benefiting-higher-income-users-despite-nominal-technology-access-equity.md
@@ -11,6 +11,10 @@ attribution:
   sourcer:
     - handle: "adepoju-et-al."
       context: "Adepoju et al. 2024, PMC11450565"
+related:
+- Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment
+reweave_edges:
+- Tailored digital health interventions achieve clinically significant systolic BP reductions at 12 months in US populations experiencing health disparities, but the effect is conditional on design specificity for these populations rather than generic deployment|related|2026-04-07
 ---
 
 # Generic digital health deployment reproduces existing disparities by disproportionately benefiting higher-income, higher-education users despite nominal technology access equity, because health literacy and navigation barriers concentrate digital health benefits upward
@@ -25,4 +29,4 @@ Relevant Notes:
 - [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]
 
 Topics:
-- [[_map]]
+- [[_map]]
\ No newline at end of file
diff --git a/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md b/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md
index e36644098..472d4c5fa 100644
--- a/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md	
+++ b/domains/health/human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs.md	
@@ -5,6 +5,10 @@ domain: health
 created: 2026-02-18
 source: "DJ Patil interviewing Bob Wachter, Commonwealth Club, February 9 2026; Stanford/Harvard diagnostic accuracy study; European colonoscopy AI de-skilling study"
 confidence: likely
+supports:
+- NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning
+reweave_edges:
+- NCT07328815 - Mitigating Automation Bias in Physician-LLM Diagnostic Reasoning|supports|2026-04-07
 ---
 
 # human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs
@@ -71,4 +75,4 @@ Relevant Notes:
 - emergent misalignment arises naturally from reward hacking as models develop deceptive behaviors without any training to deceive -- human-in-the-loop oversight is the standard safety measure against misalignment, but if humans reliably fail at oversight, this safety architecture is weaker than assumed
 
 Topics:
-- health and wellness
+- health and wellness
\ No newline at end of file
diff --git a/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md b/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md
index 9d3311b55..b491d94ed 100644
--- a/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md
+++ b/domains/health/hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md
@@ -12,8 +12,10 @@ sourcer: American Heart Association
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
 supports:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
 reweave_edges:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
 ---
 
 # Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
diff --git a/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md b/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md
index 3800de2dc..6021ca85d 100644
--- a/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md
+++ b/domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md
@@ -10,6 +10,10 @@ agent: vida
 scope: structural
 sourcer: Bloomberg / KFF Health News / BW Healthcare World
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+related:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
+reweave_edges:
+- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036|related|2026-04-07
 ---
 
 # Indian generic semaglutide exports enabled by evergreening rejection create a global access pathway before US patent expiry
@@ -20,4 +24,4 @@ The court found Dr. Reddy's presented a credible challenge to Novo's patent clai
 
 By end of 2026, semaglutide patents will have expired in 10 countries representing 48% of the global obesity burden, while US/EU/Japan patents remain active until 2031-2033. The Canada launch (May 2026) is particularly significant as the first high-income country generic launch, creating a comparable healthcare system test case.
 
-This creates a bifurcated global market where generic access expands rapidly in developing and some developed markets while the US remains under patent protection for five more years. The ruling's 'evergreening' language signals judicial skepticism toward defensive IP strategies that extend monopolies beyond primary patent terms, potentially influencing future pharmaceutical patent challenges globally.
+This creates a bifurcated global market where generic access expands rapidly in developing and some developed markets while the US remains under patent protection for five more years. The ruling's 'evergreening' language signals judicial skepticism toward defensive IP strategies that extend monopolies beyond primary patent terms, potentially influencing future pharmaceutical patent challenges globally.
\ No newline at end of file
diff --git a/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md b/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md
index 6e508a8c0..fc8947dbf 100644
--- a/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md
+++ b/domains/health/multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety-creating-accidental-harm-reduction.md
@@ -10,8 +10,12 @@ agent: vida
 scope: functional
 sourcer: Comparative analysis
 related_claims: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone", "healthcare-AI-regulation-needs-blank-sheet-redesign"]
+related:
+- Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload
+reweave_edges:
+- Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload|related|2026-04-07
 ---
 
 # Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
 
-The Mount Sinai paper frames multi-agent clinical AI as an EFFICIENCY AND SCALABILITY architecture (65x compute reduction), while NOHARM's January 2026 study showed the same architectural approach reduces clinical harm by 8% compared to solo models. The Mount Sinai paper does not cite NOHARM's harm reduction finding as a companion benefit, despite both papers recommending identical architectural solutions. This framing gap reveals how research evidence translates to market adoption: the commercial market is arriving at the right architecture for the wrong reason. The 65x cost reduction drives adoption faster than safety arguments would, but the 8% harm reduction documented by NOHARM comes along for free. This is paradoxically good for safety—if multi-agent is adopted for cost reasons, the safety benefits are implemented accidentally. The gap between research framing (multi-agent = safety) and commercial framing (multi-agent = efficiency) represents a new pattern in how clinical AI safety evidence fails to translate into market adoption arguments, even when the underlying architectural recommendation is identical.
+The Mount Sinai paper frames multi-agent clinical AI as an EFFICIENCY AND SCALABILITY architecture (65x compute reduction), while NOHARM's January 2026 study showed the same architectural approach reduces clinical harm by 8% compared to solo models. The Mount Sinai paper does not cite NOHARM's harm reduction finding as a companion benefit, despite both papers recommending identical architectural solutions. This framing gap reveals how research evidence translates to market adoption: the commercial market is arriving at the right architecture for the wrong reason. The 65x cost reduction drives adoption faster than safety arguments would, but the 8% harm reduction documented by NOHARM comes along for free. This is paradoxically good for safety—if multi-agent is adopted for cost reasons, the safety benefits are implemented accidentally. The gap between research framing (multi-agent = safety) and commercial framing (multi-agent = efficiency) represents a new pattern in how clinical AI safety evidence fails to translate into market adoption arguments, even when the underlying architectural recommendation is identical.
\ No newline at end of file
diff --git a/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md b/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md
index ca3a14d6e..e994dd5fa 100644
--- a/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md
+++ b/domains/health/multi-agent-clinical-ai-reduces-computational-cost-65x-while-maintaining-performance-under-workload.md
@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: Girish N. Nadkarni, Mount Sinai
 related_claims: ["human-in-the-loop-clinical-ai-degrades-to-worse-than-AI-alone"]
+supports:
+- Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
+reweave_edges:
+- Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption|supports|2026-04-07
 ---
 
 # Multi-agent clinical AI architecture reduces computational demands 65x compared to single-agent while maintaining performance under heavy workload
 
-Mount Sinai's peer-reviewed study distributed healthcare AI tasks (patient information retrieval, clinical data extraction, medication dose checking) among specialized agents versus a single all-purpose agent. The multi-agent architecture reduced computational demands by up to 65x while maintaining or improving diagnostic accuracy. Critically, multi-agent systems sustained quality as task volume increased, while single-agent performance degraded under heavy workload. The architectural principle mirrors clinical care team specialization: each agent optimized for its specific task performs better than one generalist attempting everything. This is the first peer-reviewed demonstration of multi-agent clinical AI entering healthcare deployment at scale. The efficiency gain is large enough to drive commercial adoption independent of safety considerations.
+Mount Sinai's peer-reviewed study distributed healthcare AI tasks (patient information retrieval, clinical data extraction, medication dose checking) among specialized agents versus a single all-purpose agent. The multi-agent architecture reduced computational demands by up to 65x while maintaining or improving diagnostic accuracy. Critically, multi-agent systems sustained quality as task volume increased, while single-agent performance degraded under heavy workload. The architectural principle mirrors clinical care team specialization: each agent optimized for its specific task performs better than one generalist attempting everything. This is the first peer-reviewed demonstration of multi-agent clinical AI entering healthcare deployment at scale. The efficiency gain is large enough to drive commercial adoption independent of safety considerations.
\ No newline at end of file
diff --git a/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md b/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
index 53576fbd6..534c9a63d 100644
--- a/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
+++ b/domains/health/regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md
@@ -14,10 +14,17 @@ supports:
 - Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years
 - FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm"}
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 reweave_edges:
 - Clinical AI chatbot misuse is a documented ongoing harm source not a theoretical risk as evidenced by ECRI ranking it the number one health technology hazard for two consecutive years|supports|2026-04-03
 - FDA's 2026 CDS guidance expands enforcement discretion to cover AI tools providing single clinically appropriate recommendations while leaving clinical appropriateness undefined and requiring no bias evaluation or post-market surveillance|supports|2026-04-03
 - {'The clinical AI safety gap is doubly structural': "FDA enforcement discretion removes pre-deployment safety requirements while MAUDE's lack of AI-specific fields means post-market surveillance cannot detect AI-attributable harm|supports|2026-04-07"}
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities|supports|2026-04-07
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
+related:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 ---
 
 # Clinical AI deregulation is occurring during active harm accumulation not after evidence of safety as demonstrated by simultaneous FDA enforcement discretion expansion and ECRI top hazard designation in January 2026
diff --git a/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md b/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
index 2d06894d9..61ba2a1e6 100644
--- a/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
+++ b/domains/health/regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence.md
@@ -12,8 +12,13 @@ sourcer: Petrie-Flom Center, Harvard Law School
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]", "[[medical LLM benchmark performance does not translate to clinical impact because physicians with and without AI access achieve similar diagnostic accuracy in randomized trials]]"]
 supports:
 - EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 reweave_edges:
 - EU Commission's December 2025 medical AI deregulation proposal removes default high-risk AI requirements shifting burden from requiring safety demonstration to allowing commercial deployment without mandated oversight|supports|2026-04-07
+- Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities|supports|2026-04-07
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
+related:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 ---
 
 # Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
diff --git a/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md b/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md
index d626954de..894f05f0f 100644
--- a/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md
+++ b/domains/health/regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence-accumulation-creating-institutional-epistemic-divergence.md
@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: Health Policy Watch
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]", "[[human-in-the-loop clinical AI degrades to worse-than-AI-alone because physicians both de-skill from reliance and introduce errors when overriding correct outputs]]"]
+supports:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
+reweave_edges:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|supports|2026-04-07
 ---
 
 # Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
 
-The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing high-risk AI requirements by up to 16 months and potentially removing them entirely for medical devices, arguing industry concerns about 'dual regulatory burden.' The same week, WHO warned that requirements for technical documentation, risk management, human oversight, and transparency would no longer apply by default to AI medical devices, creating a regulatory vacuum where 'clinicians will still be expected to use AI safely and manage edge cases, yet the regulatory system will no longer guarantee that systems are designed to support meaningful human oversight.' This is qualitatively different from industry-research tension or academic debate—it represents institutional epistemic divergence where the body responsible for patient safety (WHO) directly contradicts the body responsible for regulation (EU Commission). The Commission's proposal appears to have been developed without reference to WHO's safety evidence or the research literature on clinical AI failure modes, suggesting these institutions are operating in genuinely different epistemic frameworks—one accumulating safety evidence, the other responding to industry lobbying on regulatory burden.
+The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing high-risk AI requirements by up to 16 months and potentially removing them entirely for medical devices, arguing industry concerns about 'dual regulatory burden.' The same week, WHO warned that requirements for technical documentation, risk management, human oversight, and transparency would no longer apply by default to AI medical devices, creating a regulatory vacuum where 'clinicians will still be expected to use AI safely and manage edge cases, yet the regulatory system will no longer guarantee that systems are designed to support meaningful human oversight.' This is qualitatively different from industry-research tension or academic debate—it represents institutional epistemic divergence where the body responsible for patient safety (WHO) directly contradicts the body responsible for regulation (EU Commission). The Commission's proposal appears to have been developed without reference to WHO's safety evidence or the research literature on clinical AI failure modes, suggesting these institutions are operating in genuinely different epistemic frameworks—one accumulating safety evidence, the other responding to industry lobbying on regulatory burden.
\ No newline at end of file
diff --git a/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md b/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
index 16b000720..7bcd41e86 100644
--- a/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
+++ b/domains/health/uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md
@@ -10,8 +10,15 @@ agent: vida
 scope: structural
 sourcer: UK House of Lords Science and Technology Committee
 related_claims: ["[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
+supports:
+- UK House of Lords Science and Technology Committee
+related:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes
+reweave_edges:
+- Regulatory rollback of clinical AI oversight in EU and US during 2025-2026 represents coordinated or parallel regulatory capture occurring simultaneously with accumulating research evidence of failure modes|related|2026-04-07
+- UK House of Lords Science and Technology Committee|supports|2026-04-07
 ---
 
 # All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
 
-The UK House of Lords Science and Technology Committee launched its NHS AI inquiry on March 10, 2026, with explicit framing as an adoption failure investigation: 'Why does the NHS adoption of the UK's cutting-edge life sciences innovations often fail, and what could be done to fix it?' The inquiry examines 'key systematic barriers preventing or delaying deployment' and asks 'whether regulatory frameworks are appropriate and proportionate' — language that suggests the intent is to reduce regulatory burden rather than strengthen safety evaluation. This occurred in the same quarter as the EU AI Act rollback and FDA enforcement discretion expansion documented in Sessions 7-9. The convergence is notable because these three jurisdictions represent the world's major clinical AI regulatory regimes, and all three simultaneously prioritized deployment speed over safety evaluation. The Lords inquiry's scope includes examining 'whether current appraisal and commissioning models are fit for purpose' but frames this as a barrier to adoption, not a safety gate. No questions in the inquiry scope address clinical AI failure modes, patient safety evaluation, or the commercial-research gap on safety evidence. This pattern suggests regulatory capture at the policy level: the primary question in Parliament is not 'what are the risks of AI in healthcare?' but 'why aren't we deploying AI fast enough?'
+The UK House of Lords Science and Technology Committee launched its NHS AI inquiry on March 10, 2026, with explicit framing as an adoption failure investigation: 'Why does the NHS adoption of the UK's cutting-edge life sciences innovations often fail, and what could be done to fix it?' The inquiry examines 'key systematic barriers preventing or delaying deployment' and asks 'whether regulatory frameworks are appropriate and proportionate' — language that suggests the intent is to reduce regulatory burden rather than strengthen safety evaluation. This occurred in the same quarter as the EU AI Act rollback and FDA enforcement discretion expansion documented in Sessions 7-9. The convergence is notable because these three jurisdictions represent the world's major clinical AI regulatory regimes, and all three simultaneously prioritized deployment speed over safety evaluation. The Lords inquiry's scope includes examining 'whether current appraisal and commissioning models are fit for purpose' but frames this as a barrier to adoption, not a safety gate. No questions in the inquiry scope address clinical AI failure modes, patient safety evaluation, or the commercial-research gap on safety evidence. This pattern suggests regulatory capture at the policy level: the primary question in Parliament is not 'what are the risks of AI in healthcare?' but 'why aren't we deploying AI fast enough?'
\ No newline at end of file
diff --git a/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md b/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md
index 7561a6b10..98d0e3bc4 100644
--- a/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md
+++ b/domains/health/ultra-processed-food-consumption-increases-incident-hypertension-through-chronic-inflammation-pathway.md
@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: American Heart Association (REGARDS investigators)
 related_claims: ["[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]", "[[the epidemiological transition marks the shift from material scarcity to social disadvantage as the primary driver of health outcomes in developed nations]]"]
+supports:
+- Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
+reweave_edges:
+- Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control|supports|2026-04-07
 ---
 
 # Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
 
-The REGARDS cohort tracked 5,957 adults free from hypertension at baseline for 9.3 years (2003-2016). Participants in the highest UPF consumption quartile had 23% greater odds of developing hypertension compared to the lowest quartile, with a confirmed linear dose-response relationship. 36% of the initially hypertension-free cohort developed hypertension during follow-up. The mechanism operates through UPF-induced elevation of inflammatory biomarkers (CRP and IL-6), which trigger endothelial dysfunction and blood pressure elevation. Meta-analysis confirms each 100g/day additional UPF intake increases hypertension risk by 14.5%. The Brazilian ELSA-Brasil cohort independently replicated the 23% risk increase over 4 years, demonstrating cross-population validity. Critically, the racial disparity pattern reveals the mechanism is real, not confounded: UPF measured as % kilocalories was significant only among White adults, while UPF as % grams was significant only among Black adults, suggesting mass versus caloric density of UPF differentially reflects actual food patterns. This establishes UPF as a causal pathway, not merely a marker of socioeconomic disadvantage. The refined sugars, unhealthy fats, and chemical additives in UPF trigger inflammatory processes that damage vessel walls independently of total caloric intake.
+The REGARDS cohort tracked 5,957 adults free from hypertension at baseline for 9.3 years (2003-2016). Participants in the highest UPF consumption quartile had 23% greater odds of developing hypertension compared to the lowest quartile, with a confirmed linear dose-response relationship. 36% of the initially hypertension-free cohort developed hypertension during follow-up. The mechanism operates through UPF-induced elevation of inflammatory biomarkers (CRP and IL-6), which trigger endothelial dysfunction and blood pressure elevation. Meta-analysis confirms each 100g/day additional UPF intake increases hypertension risk by 14.5%. The Brazilian ELSA-Brasil cohort independently replicated the 23% risk increase over 4 years, demonstrating cross-population validity. Critically, the racial disparity pattern reveals the mechanism is real, not confounded: UPF measured as % kilocalories was significant only among White adults, while UPF as % grams was significant only among Black adults, suggesting mass versus caloric density of UPF differentially reflects actual food patterns. This establishes UPF as a causal pathway, not merely a marker of socioeconomic disadvantage. The refined sugars, unhealthy fats, and chemical additives in UPF trigger inflammatory processes that damage vessel walls independently of total caloric intake.
\ No newline at end of file
diff --git a/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md b/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md
index 6dce12c37..293c0edee 100644
--- a/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md
+++ b/domains/health/upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure.md
@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: American Heart Association (REGARDS investigators)
 related_claims: ["[[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]", "[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]"]
+supports:
+- Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
+reweave_edges:
+- Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate|supports|2026-04-07
 ---
 
 # Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
 
-The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces reliance on energy-dense, cheap ultra-processed options; (2) continuous UPF consumption maintains chronic systemic inflammation; (3) inflammation-driven vascular damage persists and regenerates even as antihypertensive medications (ACE inhibitors, calcium channel blockers) attempt to lower blood pressure; (4) the medication effect is partially overwhelmed by the continuous inflammatory insult; (5) result is treatment failure despite pharmacological availability and even with medication adherence. This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control—it's not primarily a medication adherence problem but a continuous environmental exposure problem. The patient can take lisinopril daily and still fail to control BP if eating UPF three times daily because that's what's affordable and available. The GLP-1 receptor agonist anti-inflammatory pathway (hsCRP reduction) provides complementary evidence: semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction—the same inflammatory mechanism that UPF drives in the opposite direction.
+The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces reliance on energy-dense, cheap ultra-processed options; (2) continuous UPF consumption maintains chronic systemic inflammation; (3) inflammation-driven vascular damage persists and regenerates even as antihypertensive medications (ACE inhibitors, calcium channel blockers) attempt to lower blood pressure; (4) the medication effect is partially overwhelmed by the continuous inflammatory insult; (5) result is treatment failure despite pharmacological availability and even with medication adherence. This mechanism explains why 76.6% of treated hypertensives fail to achieve BP control—it's not primarily a medication adherence problem but a continuous environmental exposure problem. The patient can take lisinopril daily and still fail to control BP if eating UPF three times daily because that's what's affordable and available. The GLP-1 receptor agonist anti-inflammatory pathway (hsCRP reduction) provides complementary evidence: semaglutide's cardiovascular benefit is 67% independent of weight loss, operating primarily through inflammation reduction—the same inflammatory mechanism that UPF drives in the opposite direction.
\ No newline at end of file
diff --git a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
index 7f153c3e5..8650ddfec 100644
--- a/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
+++ b/domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md
@@ -12,8 +12,12 @@ sourcer: American Heart Association
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[healthcare AI creates a Jevons paradox because adding capacity to sick care induces more demand for sick care]]"]
 supports:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
 reweave_edges:
 - Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden|supports|2026-04-07
+- Midlife CVD mortality (ages 40-64) increased in many US states after 2010 representing a reversal not merely stagnation|supports|2026-04-07
+- US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden|supports|2026-04-07
 ---
 
 # US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
diff --git a/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md b/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md
index c97e9b3b9..3fcbd0d34 100644
--- a/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md
+++ b/domains/health/us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality.md
@@ -5,6 +5,10 @@ description: "Commonwealth Fund's 2024 international comparison shows US last ov
 confidence: proven
 source: "Commonwealth Fund Mirror Mirror 2024 report (Blumenthal et al, 2024-09-19)"
 created: 2026-03-11
+supports:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
 ---
 
 # US healthcare ranks last among peer nations despite highest spending because access and equity failures override clinical quality
@@ -50,4 +54,4 @@ Relevant Notes:
 - [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]
 
 Topics:
-- domains/health/_map
+- domains/health/_map
\ No newline at end of file
diff --git a/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md b/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md
index a8d99ece0..0204e25af 100644
--- a/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md
+++ b/domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md
@@ -10,8 +10,12 @@ agent: vida
 scope: causal
 sourcer: WHO/JAMA 2024
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+supports:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
 ---
 
 # US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
 
-WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 according to CDC data. The divergence reveals that headline life expectancy improvements mask a deterioration in the quality of those years. Americans are living longer but spending a greater proportion of their lives sick and disabled. This creates a misleading narrative where public health victories (life expectancy recovery from COVID, opioid crisis improvements) obscure the ongoing failure to maintain functional health. The 12.4-year gap means the average American spends nearly 16% of their life in poor health, and this percentage is growing. For productive capacity and economic output, the relevant metric is healthy years, not total years alive—and by this measure, the US is moving backward despite record healthcare spending.
+WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 according to CDC data. The divergence reveals that headline life expectancy improvements mask a deterioration in the quality of those years. Americans are living longer but spending a greater proportion of their lives sick and disabled. This creates a misleading narrative where public health victories (life expectancy recovery from COVID, opioid crisis improvements) obscure the ongoing failure to maintain functional health. The 12.4-year gap means the average American spends nearly 16% of their life in poor health, and this percentage is growing. For productive capacity and economic output, the relevant metric is healthy years, not total years alive—and by this measure, the US is moving backward despite record healthcare spending.
\ No newline at end of file
diff --git a/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md b/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md
index e95739ecd..aea3764b1 100644
--- a/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md
+++ b/domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md
@@ -10,8 +10,12 @@ agent: vida
 scope: structural
 sourcer: Garmany et al. (Mayo Clinic)
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
+supports:
+- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
+reweave_edges:
+- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics|supports|2026-04-07
 ---
 
 # The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
 
-The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Australia (12.1 years), New Zealand (11.8 years), UK (11.3 years), and Norway (11.2 years). The finding is particularly striking because the US has the highest healthcare spending per capita globally, yet produces the worst healthy-to-sick ratio among developed nations. The study found gaps positively associated with burden of noncommunicable diseases and total morbidity, suggesting the US gap reflects structural healthcare system failures in prevention and chronic disease management rather than insufficient resources. This pattern holds even in affluent US populations, ruling out poverty as the primary explanation. The global healthspan-lifespan gap widened from 8.5 years (2000) to 9.6 years (2019), a 13% increase, but the US deterioration is more severe than the global trend.
+The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Australia (12.1 years), New Zealand (11.8 years), UK (11.3 years), and Norway (11.2 years). The finding is particularly striking because the US has the highest healthcare spending per capita globally, yet produces the worst healthy-to-sick ratio among developed nations. The study found gaps positively associated with burden of noncommunicable diseases and total morbidity, suggesting the US gap reflects structural healthcare system failures in prevention and chronic disease management rather than insufficient resources. This pattern holds even in affluent US populations, ruling out poverty as the primary explanation. The global healthspan-lifespan gap widened from 8.5 years (2000) to 9.6 years (2019), a 13% increase, but the US deterioration is more severe than the global trend.
\ No newline at end of file
diff --git a/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md b/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
index eaacbf94a..c1d8b775f 100644
--- a/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
+++ b/domains/space-development/breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure-signals-sbsp-credibility-as-climate-technology-category.md
@@ -10,8 +10,12 @@ agent: astra
 scope: functional
 sourcer: Data Center Dynamics / PRNewswire
 related_claims: ["[[power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited]]"]
+supports:
+- Aetherflux
+reweave_edges:
+- Aetherflux|supports|2026-04-07
 ---
 
 # Breakthrough Energy Ventures' investment in Aetherflux's orbital solar infrastructure signals that space-based solar power has achieved credibility as a climate technology investment category at institutional investor level
 
-Breakthrough Energy Ventures, Bill Gates' climate-focused investment fund, participated in Aetherflux's $50M Series A alongside a16z, NEA, Index, and Interlagos. BEV's investment thesis centers on climate-critical technologies with potential for significant emissions reduction. Their participation in Aetherflux validates that SBSP is now taken seriously as a climate solution at the institutional investor level, not merely as a space technology or science fiction concept. This is significant because BEV conducts rigorous technical and economic due diligence - their investment suggests that the physics and economics of laser-based power transmission from LEO have crossed a credibility threshold. The ODC framing provides the near-term business justification (AI compute revenue), but BEV's interest is likely driven by the long-term SBSP potential for clean energy generation. This represents a shift in how SBSP is categorized: from 'space infrastructure' to 'climate technology,' which opens access to a different pool of capital with different risk tolerances and time horizons.
+Breakthrough Energy Ventures, Bill Gates' climate-focused investment fund, participated in Aetherflux's $50M Series A alongside a16z, NEA, Index, and Interlagos. BEV's investment thesis centers on climate-critical technologies with potential for significant emissions reduction. Their participation in Aetherflux validates that SBSP is now taken seriously as a climate solution at the institutional investor level, not merely as a space technology or science fiction concept. This is significant because BEV conducts rigorous technical and economic due diligence - their investment suggests that the physics and economics of laser-based power transmission from LEO have crossed a credibility threshold. The ODC framing provides the near-term business justification (AI compute revenue), but BEV's interest is likely driven by the long-term SBSP potential for clean energy generation. This represents a shift in how SBSP is categorized: from 'space infrastructure' to 'climate technology,' which opens access to a different pool of capital with different risk tolerances and time horizons.
\ No newline at end of file
diff --git a/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md b/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md
index 849609c9a..16054729c 100644
--- a/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md	
+++ b/domains/space-development/commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030.md	
@@ -11,6 +11,9 @@ supports:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s
 reweave_edges:
 - Vast is building the first commercial space station with Haven 1 launching 2027 funded by Jed McCaleb 1B personal commitment and targeting artificial gravity stations by the 2030s|supports|2026-04-04
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|related|2026-04-07
+related:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
 ---
 
 # commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030
diff --git a/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md b/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
index 03e258ede..30a233245 100644
--- a/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
+++ b/domains/space-development/orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md
@@ -10,8 +10,12 @@ agent: astra
 scope: structural
 sourcer: Data Center Dynamics / The Register / Space.com
 related_claims: ["[[power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]"]
+supports:
+- Aetherflux
+reweave_edges:
+- Aetherflux|supports|2026-04-07
 ---
 
 # Orbital data centers and space-based solar power share identical infrastructure requirements in sun-synchronous orbit creating a dual-use architecture where near-term compute revenue cross-subsidizes long-term energy transmission development
 
-Aetherflux's 'Galactic Brain' orbital data center reveals a fundamental architectural convergence: both ODC and SBSP require continuous solar exposure in sun-synchronous orbit (~500-600 km altitude, 97° inclination). The company is explicitly building both capabilities simultaneously - processing AI workloads in orbit while developing laser power transmission to Earth. This is not a coincidence but a physical necessity: the satellites need continuous solar power for compute operations, and the same infrastructure can beam excess power to Earth. The dual-use architecture solves a critical problem for SBSP development: how to justify the capital expenditure for orbital solar infrastructure before power beaming is commercially viable. ODC provides near-term revenue (AI compute services) that cross-subsidizes the long-term SBSP development. The Q1 2027 timeline for commercial ODC operations precedes any realistic SBSP commercialization timeline, confirming the revenue bridge strategy. This architectural convergence means that companies building ODC infrastructure are simultaneously building SBSP infrastructure, potentially accelerating SBSP development through a different economic pathway than direct energy-focused investment.
+Aetherflux's 'Galactic Brain' orbital data center reveals a fundamental architectural convergence: both ODC and SBSP require continuous solar exposure in sun-synchronous orbit (~500-600 km altitude, 97° inclination). The company is explicitly building both capabilities simultaneously - processing AI workloads in orbit while developing laser power transmission to Earth. This is not a coincidence but a physical necessity: the satellites need continuous solar power for compute operations, and the same infrastructure can beam excess power to Earth. The dual-use architecture solves a critical problem for SBSP development: how to justify the capital expenditure for orbital solar infrastructure before power beaming is commercially viable. ODC provides near-term revenue (AI compute services) that cross-subsidizes the long-term SBSP development. The Q1 2027 timeline for commercial ODC operations precedes any realistic SBSP commercialization timeline, confirming the revenue bridge strategy. This architectural convergence means that companies building ODC infrastructure are simultaneously building SBSP infrastructure, potentially accelerating SBSP development through a different economic pathway than direct energy-focused investment.
\ No newline at end of file
diff --git a/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md b/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md
index 32b72daff..ec2699700 100644
--- a/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md
+++ b/domains/space-development/phase-2-funding-freeze-disproportionately-harms-design-phase-programs-dependent-on-nasa-capital-for-manufacturing-transition.md
@@ -10,8 +10,12 @@ agent: astra
 scope: causal
 sourcer: Mike Turner, Exterra JSC
 related_claims: ["[[commercial space stations are the next infrastructure bet as ISS retirement creates a void that 4 companies are racing to fill by 2030]]", "[[governments are transitioning from space system builders to space service buyers which structurally advantages nimble commercial providers]]"]
+supports:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
+reweave_edges:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|supports|2026-04-07
 ---
 
 # NASA CLD Phase 2 funding freeze creates existential risk for design-phase programs that lack private capital to self-fund manufacturing transition
 
-The Phase 2 CLD funding freeze has asymmetric impact across the three-tier commercial station market. Programs in manufacturing phase (Axiom with $2.55B private capital, Vast with undisclosed funding) can proceed independently of NASA Phase 2 awards. Programs in design-to-manufacturing transition (Starlab with $40B financing facility) have institutional backing to bridge the gap. But Orbital Reef, still in design phase with only $172M Phase 1 NASA funding split between Blue Origin and Sierra Space, faces a capital structure problem: the transition from design maturity to manufacturing requires substantial investment in tooling, facilities, and flight hardware production that Phase 1 funding was not sized to cover. Turner's analysis suggests Orbital Reef was "counting on Phase 2 to fund the transition from design to manufacturing — which is exactly Orbital Reef's position." The freeze creates existential dependency: without Phase 2 or equivalent private capital infusion, Orbital Reef cannot progress to manufacturing while competitors continue advancing. This validates the fragility of second-tier players in capital-intensive infrastructure races. The $40B Starlab financing facility is particularly notable as it represents institutional lender confidence in future NASA revenue sufficient to service debt, effectively betting on Phase 2 or equivalent service contracts materializing despite the current freeze.
+The Phase 2 CLD funding freeze has asymmetric impact across the three-tier commercial station market. Programs in manufacturing phase (Axiom with $2.55B private capital, Vast with undisclosed funding) can proceed independently of NASA Phase 2 awards. Programs in design-to-manufacturing transition (Starlab with $40B financing facility) have institutional backing to bridge the gap. But Orbital Reef, still in design phase with only $172M Phase 1 NASA funding split between Blue Origin and Sierra Space, faces a capital structure problem: the transition from design maturity to manufacturing requires substantial investment in tooling, facilities, and flight hardware production that Phase 1 funding was not sized to cover. Turner's analysis suggests Orbital Reef was "counting on Phase 2 to fund the transition from design to manufacturing — which is exactly Orbital Reef's position." The freeze creates existential dependency: without Phase 2 or equivalent private capital infusion, Orbital Reef cannot progress to manufacturing while competitors continue advancing. This validates the fragility of second-tier players in capital-intensive infrastructure races. The $40B Starlab financing facility is particularly notable as it represents institutional lender confidence in future NASA revenue sufficient to service debt, effectively betting on Phase 2 or equivalent service contracts materializing despite the current freeze.
\ No newline at end of file
diff --git a/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md b/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md
index 21880ceb7..e077fdcc1 100644
--- a/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md
+++ b/domains/space-development/policy-driven-funding-freezes-can-be-as-damaging-to-commercial-space-timelines-as-technical-delays.md
@@ -10,8 +10,12 @@ agent: astra
 scope: causal
 sourcer: SpaceNews
 related_claims: ["[[space governance gaps are widening not narrowing because technology advances exponentially while institutional design advances linearly]]", "[[designing coordination rules is categorically different from designing coordination outcomes as nine intellectual traditions independently confirm]]"]
+supports:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs
+reweave_edges:
+- Anchor customer uncertainty is now the binding constraint for commercial station programs not technical capability or launch costs|supports|2026-04-07
 ---
 
 # Policy-driven funding freezes can be as damaging to commercial space program timelines as technical delays because they create capital formation uncertainty
 
-The CLD Phase 2 freeze demonstrates that governance uncertainty creates timeline risk equivalent to technical risk. The program had been planned since late 2025 with an April 2026 award date. Proposals were submitted December 1, 2025. The freeze occurred January 28, 2026 with no replacement timeline. This creates a capital formation problem: companies that had planned development timelines around anticipated NASA funding now face either raising replacement capital (as Axiom did with $350M in February) or delaying programs until policy clarity emerges. The mechanism is distinct from technical delays: technical problems are typically bounded (you know what needs to be solved), while policy uncertainty is unbounded (you don't know when or if the program will resume, or in what form). The freeze also occurred while Space Force budget increased 39% to $40B, suggesting defense space investment continued while civil space anchor customer role was under review. This creates a divergence where technical capability and launch infrastructure continue advancing while the governance framework for utilizing them stalls.
+The CLD Phase 2 freeze demonstrates that governance uncertainty creates timeline risk equivalent to technical risk. The program had been planned since late 2025 with an April 2026 award date. Proposals were submitted December 1, 2025. The freeze occurred January 28, 2026 with no replacement timeline. This creates a capital formation problem: companies that had planned development timelines around anticipated NASA funding now face either raising replacement capital (as Axiom did with $350M in February) or delaying programs until policy clarity emerges. The mechanism is distinct from technical delays: technical problems are typically bounded (you know what needs to be solved), while policy uncertainty is unbounded (you don't know when or if the program will resume, or in what form). The freeze also occurred while Space Force budget increased 39% to $40B, suggesting defense space investment continued while civil space anchor customer role was under review. This creates a divergence where technical capability and launch infrastructure continue advancing while the governance framework for utilizing them stalls.
\ No newline at end of file
diff --git a/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md b/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
index c307d4a19..559205db9 100644
--- a/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
+++ b/domains/space-development/space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md
@@ -10,8 +10,12 @@ agent: astra
 scope: structural
 sourcer: TechCrunch / Aetherflux
 related_claims: ["[[the space manufacturing killer app sequence is pharmaceuticals now ZBLAN fiber in 3-5 years and bioprinted organs in 15-25 years each catalyzing the next tier of orbital infrastructure]]", "[[launch cost reduction is the keystone variable that unlocks every downstream space industry at specific price thresholds]]", "[[power is the binding constraint on all space operations because every capability from ISRU to manufacturing to life support is power-limited]]"]
+supports:
+- Aetherflux
+reweave_edges:
+- Aetherflux|supports|2026-04-07
 ---
 
 # Space-based solar power and orbital data centers share infrastructure making ODC the near-term revenue bridge to long-term SBSP
 
-Aetherflux's architecture demonstrates that SBSP and ODC are not separate technologies but sequential applications of the same physical infrastructure. The company's 2026 demonstration mission uses LEO satellites with continuous solar exposure and infrared laser transmission—the exact same hardware serves both use cases. CEO Baiju Bhatt stated that 'about a year ago' (late 2024) the team realized powering AI workloads by placing compute in orbit and feeding via space-based solar power is 'more economically attractive' than transmitting energy to terrestrial facilities. This is not a pivot but a sequencing insight: ODC provides near-term revenue (Galactic Brain targeting Q1 2027 commercial operation) while SBSP remains the long-term value case. The infrastructure investment is identical—LEO constellation, solar arrays, infrared laser transmission systems—but ODC monetizes immediately through compute services while SBSP requires regulatory approval and grid integration. This creates a capital-efficient path where early ODC revenue funds the same satellite network that eventually enables SBSP, rather than requiring separate infrastructure investments for each use case. The DoD's interest in 'power transmission from LEO' for forward operating locations adds a third revenue stream (military logistics) using the same physical system.
+Aetherflux's architecture demonstrates that SBSP and ODC are not separate technologies but sequential applications of the same physical infrastructure. The company's 2026 demonstration mission uses LEO satellites with continuous solar exposure and infrared laser transmission—the exact same hardware serves both use cases. CEO Baiju Bhatt stated that 'about a year ago' (late 2024) the team realized powering AI workloads by placing compute in orbit and feeding via space-based solar power is 'more economically attractive' than transmitting energy to terrestrial facilities. This is not a pivot but a sequencing insight: ODC provides near-term revenue (Galactic Brain targeting Q1 2027 commercial operation) while SBSP remains the long-term value case. The infrastructure investment is identical—LEO constellation, solar arrays, infrared laser transmission systems—but ODC monetizes immediately through compute services while SBSP requires regulatory approval and grid integration. This creates a capital-efficient path where early ODC revenue funds the same satellite network that eventually enables SBSP, rather than requiring separate infrastructure investments for each use case. The DoD's interest in 'power transmission from LEO' for forward operating locations adds a third revenue stream (military logistics) using the same physical system.
\ No newline at end of file
diff --git a/entities/health/uk-house-of-lords-science-technology-committee.md b/entities/health/uk-house-of-lords-science-technology-committee.md
index 799ea7934..6256214ce 100644
--- a/entities/health/uk-house-of-lords-science-technology-committee.md
+++ b/entities/health/uk-house-of-lords-science-technology-committee.md
@@ -6,6 +6,10 @@ domain: health
 founded: N/A
 status: active
 headquarters: London, UK
+related:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
+reweave_edges:
+- All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026|related|2026-04-07
 ---
 
 # UK House of Lords Science and Technology Committee